ストックスクリーナーアプリを入手
1.68
17.24%
-0.35
プレマーケット:
1.86
0.18
+10.71%
前日終値:
$2.03
開ける：
$1.99
24時間の取引高:
566.48K
Relative Volume:
5.75
時価総額：
$52.31M
収益：
-
当期純損益:
$-69.00M
株価収益率:
-0.6043
EPS:
-2.78
ネットキャッシュフロー:
$-55.26M
1週間 パフォーマンス:
-68.83%
1か月 パフォーマンス:
-68.36%
6か月 パフォーマンス:
-75.93%
1年 パフォーマンス:
-76.83%
1日の値動き範囲:
$1.56
$1.99
1週間の範囲:
$1.56
$4.42
52週間の値動き範囲:
$1.56
$11.90
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
名前
Acrivon Therapeutics Inc
セクター
電話
617-207-8979
住所
480 ARSENAL WAY, SUITE 100, WATERTOWN
ACRV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.68 | 52.31M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-31 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-12-15 | 再開されました | Jefferies | Buy |
| 2023-10-05 | 開始されました | Maxim Group | Buy |
| 2023-06-02 | 開始されました | Oppenheimer | Outperform |
| 2023-05-08 | 開始されました | BMO Capital Markets | Outperform |
| 2023-04-27 | 開始されました | Ladenburg Thalmann | Buy |
| 2023-04-20 | 開始されました | H.C. Wainwright | Buy |
| 2022-12-12 | 開始されました | Cowen | Outperform |
| 2022-12-12 | 開始されました | Jefferies | Buy |
| 2022-12-12 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Acrivon Therapeutics Inc (ACRV) 最新ニュース
Q1 Earnings Forecast for ACRV Issued By HC Wainwright - Defense World
Acrivon Therapeutics (NASDAQ:ACRV) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Contrast - Defense World
H.C. Wainwright maintains Acrivon stock Buy rating, $19 target By Investing.com - Investing.com Australia
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know - MSN
Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer - TipRanks
Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks - Yahoo Finance
H.C. Wainwright maintains Acrivon stock Buy rating, $19 target - Investing.com India
HC Wainwright Has Lowered Expectations for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World
FY2029 Earnings Estimate for ACRV Issued By HC Wainwright - Defense World
Cantor Fitzgerald Reaffirms “Overweight” Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c) - TipRanks
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Hard-to-Treat Endometrial Cancer - Stock Titan
Acrivon Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Long Term Trading Analysis for (ACRV) - news.stocktradersdaily.com
Acrivon narrows focus for ACR-368 in endometrial cancer - BioWorld MedTech
JMP maintains Acrivon stock with $17 target following update By Investing.com - Investing.com Australia
Acrivon Therapeutics stock target cut to $19 by H.C. Wainwright - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Crude Oil Gains Over 1%; Cintas Shares Jump After Q3 Earnings - Benzinga
Nasdaq Down 1%; Dollar Tree To Sell Family Dollar Business For $1 Billion - Benzinga
Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer - Endpoints News
Cantor Fitzgerald maintains Overweight on Acrivon stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains Overweight on Acrivon stock - Investing.com
JMP maintains Acrivon stock with $17 target following update - Investing.com India
Acrivon Therapeutics’ SWOT analysis: innovative oncology firm’s stock potential By Investing.com - Investing.com Australia
Citizens JMP reiterates Acrivon stock with $17 target By Investing.com - Investing.com South Africa
Acrivon Therapeutics’ SWOT analysis: innovative oncology firm’s stock potential - Investing.com
Citizens JMP reiterates Acrivon stock with $17 target - Investing.com
Acrivon Therapeutics: Promising Oncology Advancements and Strategic Positioning Justify Buy Rating - TipRanks
Acrivon Therapeutics (ACRV) to Release Quarterly Earnings on Thursday - Defense World
Acrivon Therapeutics to Host Corporate R&D Event to Provide - GlobeNewswire
Acrivon Unveils Next-Gen Cancer Platform: Key Updates from Leading Oncology Experts - StockTitan
Acrivon Therapeutics to Host Virtual R&D Event on March 25, 2025, Featuring Updates on ACR-368 and ACR-2316 - Nasdaq
Acrivon Therapeutics Names Adam Levy as CFO -March 17, 2025 at 05:36 am EDT - Marketscreener.com
(ACRV) Investment Report - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 33.7% in February - The AM Reporter
Acrivon Therapeutics appoints new CFO as predecessor steps down By Investing.com - Investing.com Australia
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Decreases By 33.7% - Defense World
Acrivon Therapeutics appoints new CFO as predecessor steps down - Investing.com India
Acrivon Therapeutics Appoints New Chief Financial Officer - TipRanks
Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Price Target at $23.67 - Defense World
Acrivon Therapeutics Stock Is Soaring Tuesday: What's Going On? - MSN
When (ACRV) Moves Investors should Listen - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Average Target Price from Analysts - Defense World
Acrivon Therapeutics Inc (ACRV) 財務データ
収益
当期純利益
現金流量
EPS
3.89%
0.13%
大文字化:
|
ボリューム (24 時間):